XILLIX FDA APPROVED Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XILLIX FDA APPROVED

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Raymond McIsaac who wrote (267)	5/27/1998 2:07:00 PM
From: don jackson	Read Replies (1) of 572

Xillix to Sell Its Equity Interest in Oncometrics RICHMOND, BRITISH COLUMBIA--Xillix has entered into a letter of intent from AccuMed International (AccuMed), of Chicago, Illinois, (NASDAQ:ACMCD) whereby Xillix will sell their final one-third interest in Oncometrics Imaging Corp. (Oncometrics) to AccuMed. AccuMed acquired a two-thirds ownership position in Oncometrics in October 1996 to commercialize their quantitative microscopy imaging systems technology and the results from their advanced research in early cancer research. The terms of the purchase agreement were not disclosed. "Our focus at Xillix is to continue to develop the Xillix LIFE Fluorescence Endoscopy System platform of products," said Pierre Leduc, President and CEO. "AccuMed's focus on cytometry will result in a product that will provide better screening technology and enable physicians to better assess diseases. The development at Oncometrics will compliment AccuMed's business objective of developing an assay for early cancer screening. This represents a significant opportunity for expanded use of the Xillix LIFE Fluorescence Endoscopy System platform of products."

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next